Oral drug shows promise for severe fatty liver in Phase 2b trial Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.

https://www.drugdiscoverynews.com/oral-drug-shows-promise-for-severe-fatty-liver-in-phase-2b-trial-16209